Augmentation of Antimetastatic Activity of Interferon and Tumor Necrosis Factor by Heparin

References

• Helson L., Green S., Carswell E., Old L. J. Effect of tumor necrosis factor on cultured melanoma cells. Nature 1975; 258: 731
   PubMed Web of Science ®Google Scholar
• Haranaka K., Satomi N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer 1984; 34: 263
   PubMed Web of Science ®Google Scholar
• Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943
   PubMed Web of Science ®Google Scholar
• Williamson B. D., Carswell E. A., Rubin B. Y., Prendergast J. S., Old L. J. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc. Natl. Acad. Sci. USA 1983; 80: 5397
   PubMed Web of Science ®Google Scholar
• Ruff M. R., Gifford G. E. Tumor necrosis factor, in Lymphokines. Academic Press, New York 1981; Vol 2
   Google Scholar
• Tsujimoto M., Yip Y. K., Vilcek J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Cell Biol. 1985; 82: 7626
   Google Scholar
• Ostensen M. E., Thiele D. L., Lipsky P. E. Tumor necrosis factor enhances cytolytic activity of human natural killer cells. J. Immunol. 1987; 138: 4185
   PubMed Web of Science ®Google Scholar
• Vilcek J., Gray P. W., Rinderknecht E., Sevastopoulos C. G. Interferon-gamma: a lymphokine for all seasons. Lymphokines, E. p.I Pick. Academic Press, Orlando 1984
   Google Scholar
• Ortaldo J. R. Regulation of natural killer activity. Cancer and Metast. Rev. 1987; 6: 637
   PubMed Web of Science ®Google Scholar
• Taguchi T., Kimoto Y., Tanji Y., Abe S., Nakano K., Sohmura Y. Augmentation of cytotoxic activity of recombinant human tumor necrosis factor (rHu-TNF) by recombinant human interferon-gamma (rHu-IFN-gamma). J. Biol. Res. Mod. 1987; 6: 599
   Google Scholar
• Brouckaert P. G.G., Leroux-Roels G. G., Guisez Y., Tavernier J., Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF. alone and in combination with murine IFN, on a syngeneic murine melanoma, Int. J. cancer 1986; 38: 763
   Google Scholar
• McMillan T. J., Rao J., Everett C. A., Hart I. R. Interferon-induced alterations in metastatic capacity. class-1 antigen expression and natural killer cell sensitivity of melanoma cells, Int. J. Cancer 1987; 40: 659
   Google Scholar
• Aggarwal B., Eesaulu T. E., Hass P. E. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature (Lond.) 1985; 318: 665
   PubMed Web of Science ®Google Scholar
• Tsujimoto M., Yip Y. K., Vilceck J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J. Immunol. 1986; 136: 2441
   PubMed Web of Science ®Google Scholar
• Ruggiero V., Tavernier J., Fiers W., Baglioni C. Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J. Immunol. 1986; 136: 2445
   PubMed Web of Science ®Google Scholar
• Dinarello C. A., Cannon J. G., Wolff S. M., Bernheirm H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A., Jr., O'Connor J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 1986; 163: 1433
   PubMed Web of Science ®Google Scholar
• Chapekar M. S., Glazer R. I. The synergistic cytocidal effect produced by immune interferon and tumor necrosis factor in HT-29 cells is associated with inhibition of rRNA processing and (2′,5′)oligo(A) activation of RNase L. Biochem. Biophys. Res. commun. 1988; 151: 1180
   PubMed Web of Science ®Google Scholar
• Talmadge J. E., Bowersox O., Tribble H., Lee S. H., Shepard M., Leggitt D. Toxicity of tumor necrosis factor is synergistic with IFN-gamma and can be reduced with cyclooxygenase inhibitors. Am. J. Pathol. 1987; 128: 410
   PubMed Web of Science ®Google Scholar
• Bevilacqua M. P., Pober J. S., Majeau G. R., Fiers W., Cotran R. S., Gimbrone M. S. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc. Natl. Acad. Sci., (USA) 1986; 83: 4533
   PubMed Web of Science ®Google Scholar
• Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 1986; 163: 740
   PubMed Web of Science ®Google Scholar
• Regelson W. The antimitotic activity of polyanions (antitumor. antiviral, and antibacterial action of heparin, heparinoids, anionic dyes, and synthetic polymers), Adv. Chemotherapy 1968; 3: 303
   Google Scholar
• Jaques L. B. The new understanding of the drug heparin. Chest 1985; 5: 751
   Google Scholar
• Eskinazi D. P., Perna J. J., Ershow A. G., Sharrow S. O. Effects of heparin on in vitro immune parameters. J. Biol. Resp. Mod. 1988; 7: 173
   Google Scholar
• Gorelik E., Bere W. W., Herberman R. B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int. J. Cancer 1984; 33: 87
   PubMed Web of Science ®Google Scholar
• Irimura T., Nakajima M., Nicolson G. L. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 1986; 25: 5322
   PubMed Web of Science ®Google Scholar
• Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res. 1987; 47: 809
   Google Scholar
• Abdallah R. M., Starkey J. R., Meadows G. G. Alcohol and related dietary effects on mouse natural killer-cell activity. Immunology 1983; 50: 131
   Google Scholar
• Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX: the quantitation of natural killer cell activity. J. Clin. Immunol. 1981; 1: 51
   PubMed Web of Science ®Google Scholar
• Clauss A. Gerinnungs physiologische schenell methods zur bestimmung des fibrinogens. Acta Haematol. 1957; 17: 237
   PubMedGoogle Scholar
• Ranby M., Norrman B., Wallen P. A sensitive assay for tissue plasminogen activator. Thromb. Res. 1982; 27: 743
   PubMed Web of Science ®Google Scholar
• Talmadge J. E., Tribble H. R., Pennington R. W., Phillips H., Wiltrout R. H. Immunomodulatory and Immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 1987; 47: 2563
   PubMed Web of Science ®Google Scholar
• Edwards B. S., Merritt J. A., Fuhlbrigge R. C., Borden E. C. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J. Clin. Invest. 1908; 75, 1985
   Google Scholar
• Talmadge J. E., Herberman R. B., Chirgos M. A., Maluish A. E., Schneider M. A., Adams J. S., Phillips H., Thurman G. B., Varesio L., Long C. W., Oldham R. K., Wiltrout R. H. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J. Immunol. 1985; 135: 2483
   Google Scholar
• Ortaldo J. R. Regulation of natural killer activity. Cancer and Metas. Rev. 1987; 6: 637
   PubMed Web of Science ®Google Scholar
• Bravo Cuellar A., Martin Ruiz J. L., Orbach-Arbouys S. Decreased natural killer cell activity after prolonged administration of interferon in cancer patients. Immunol. Letters 1985; 10: 137
   Google Scholar
• Pineo G. F., Regoeczi E., Hatton M. W.C., Brain M. C. The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinoma. J. Lab. Clin. Med. 1973; 82: 255
   PubMedGoogle Scholar
• Gordon S. G., Franks J. J., Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb. Res. 1975; 6: 127
   PubMed Web of Science ®Google Scholar
• Colucci M., Curatolo L., Donati M. B., Semeraro N. Cancer cell procoagulant activity: evaluation by an amydolytic assay. Thromb. Res. 1980; 18: 589
   Google Scholar
• Rickles F. R., Hancock W. W., Edwards R. L., Zacharski L. R. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Sem. Thromb. Hemost. 1988; 14: 88
   Google Scholar
• Miller S. P., Sanchez-Avalos J., Stefanski T., Zucherman L. Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 1967; 20: 1452
   PubMed Web of Science ®Google Scholar
• Brugarolas A., Mink I. B., Elias E. G., Mittelman A. Correlation of hyperfibrinogenemia with major thromboembolism in patients with cancer. SGO 1973; 136: 75
   Google Scholar
• Agostino D., Cliffton E. E. Fibrinogen levels and pulmonary metastasis in rats. Arch. Pathol. 1969; 87: 141
   Google Scholar
• Laki K. Fibrinogen and metastasis. J. Med. 1974; 5: 32
   PubMedGoogle Scholar
• Peterson H. I., Larsson S., Zettergren L. Fibrinolysis in human bronchogenic carcinoma. Eur. J. Cancer 1975; 11: 277
   Google Scholar
• Malone J. M., Wangensteen S. L., Moore W. S., Keown K. The fibrinolytic system a key to tumor metastasis?. Ann. Surg. 1979; 190: 342
   Google Scholar
• Colombi M., Rebessi L., Boiocchi M., Barlati S. Relationship between circulating plasminogen activators and tumor development in mice. Cancer Res. 1986; 46: 5748
   Google Scholar
• Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nilsen L. S., Skriver L. Plasminogen activators. tissue degradation, and cancer, Adv. Cancer Res. 1985; 44: 140
   Google Scholar
• Fareed J., Walenga J. M., Hoppensteadt D. A., Messmore H. L. Studies on the profibrinolytic actions of heparin and its fractions. Sem. Thromb. Hem. 1985; 11: 199
   PubMedGoogle Scholar
• Beutler B., Mahoney J., LeTrang N., Pekala P., Cerami A. Purification of cachectin. a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells, J. Exp. Med. 1985; 161: 984
   Google Scholar
• Kurzrock R., Rohde M. R., Quesada J. R., Gianturco S. H., Bradley W. A., Sherwin S. A., Gutterman J. U. Recombinant gamma-interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J. Exp. Med. 1986; 164: 1093
   PubMed Web of Science ®Google Scholar
• Watanabe N., Niitsu Y., Yamauchi N., Umeno H., Sone H., Neda H., Urushizaki I. Antitumor synergism between recombinant human tumor necrosis factor and recombinant human interferon-r. J. Biol. Resp. Mod. 1988; 7: 24
   PubMedGoogle Scholar
• Bollon A. P., Berent S. L., Torczynski R. M., Hill N. O., Lemeshev Y., Hill J. M., Jia F. L., Joher A., Pichyangkul S., Khan A. Human cytokines. tumor necrosis factor, and interferons: gene cloning, animal studies, and clinical trials, J. Cell Biochem 1988; 36: 353
   Google Scholar
• Rickles F. R., Hancock W. W. Antimetastatic agents. II. Summary of the interactions of tumor cells with blood coagulation factors. platelets, fibrinolytic factors, and inflammatory cells and their soluble mediators: Potential for therapeutic interventions, Semin. Thromb. Hemostat. 1988; 14: 126
   Google Scholar
• Yamamoto H., Fuyama S., Arai S., Sendo F. Inhibition of mouse natural killer cytotoxicity by heparin. Cell. Immunol. 1985; 96: 409
   Google Scholar
• Zoller M., Strubel A., Hammerling G., Andrighetto G., Raz A., Ben-Ze'ev A. Interferon-gamma treatment of B16 melanoma cells: Opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread. Int. J. Cancer 1988; 41: 256
   Google Scholar
• Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev. 1982; 1: 45
   PubMedGoogle Scholar
• Barlozzari T., Leonhardt J., Wiltrout R. H., Herberman R. B., Reynolds C. W. Direct evidence for the role of NK cells in the inhibition of tumor metastasis. J. Immunol. 1985; 134: 2783
   PubMed Web of Science ®Google Scholar
• Wiltrout R. H., Herberman R. B., Zhang S-R., Chirigos M. A., Ortaldo J. R., Green K. M., Talmadge J. E. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J. Immunol. 1985; 134: 4267
   PubMed Web of Science ®Google Scholar